FC
APLS

Finepoint Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Finepoint Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-241,690
Closed -$22M – 29
2023
Q2 		$22M Sell
241,690
-42,000
-15% -$3.62M 7.62% 1
2023
Q1 		$18.7M Sell
283,690
-51,200
-15% -$2.95M 7.15% 2
2022
Q4 		$17.3M Buy
334,890
+68,800
+26% +$3.65M 5.6% 8
2022
Q3 		$18.2M Sell
266,090
-52,310
-16% -$3.1M 5.98% 6
2022
Q2 		$14.4M Buy
+318,400
New +$14.5M 4.98% 10

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Finepoint Capital's APLS Position: Q3 2023 in Review

Finepoint Capital sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 241,690 shares — an estimated $22M sold.

Finepoint Capital first reported a position in APLS in Q2 2022 and held it in 5 quarters. The position peaked at $22M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Finepoint Capital reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Finepoint Capital sold 241,690 Apellis Pharmaceuticals shares in Q3 2023, an estimated $22M.
  • Finepoint Capital first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Finepoint Capital's Apellis Pharmaceuticals position peaked at $22M in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Finepoint Capital's 13F filing for Q3 2023, filed 13 Nov 2023.